Opus Genetics (IRD) announced the appointment of Rob Gagnon, CPA, MBA, as CFO. Gagnon joins Opus from Remix Therapeutics, where he served as CFO and led the company’s finance function, strategic financing process, fundraising efforts and IPO preparation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Promising Developments and Financial Stability Drive Buy Rating for Opus Genetics
- Opus Genetics announces FDA clearance of IND application for OPGx-BEST1
- Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating
- Opus Genetics reports Q2 EPS (12c) vs (30c) last year
- Opus Genetics Secures Funding for Gene Therapy Development